KeyBank National Association
SUPN icon

KeyBank National Association’s Supernus Pharmaceuticals SUPN Stock Holding History

KeyBank National Association’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,751
Closed -$213K – 1027
2019
Q3 		$213K Sell
7,751
-7,950
-51% -$236K ﹤0.01% 931
2019
Q2 		$520K Sell
15,701
-7,337
-32% -$251K ﹤0.01% 734
2019
Q1 		$807K Sell
23,038
-4,025
-15% -$150K ﹤0.01% 589
2018
Q4 		$899K Buy
27,063
+11,024
+69% +$474K 0.01% 503
2018
Q3 		$808K Sell
16,039
-3,069
-16% -$152K ﹤0.01% 628
2018
Q2 		$1.14M Buy
+19,108
New +$990K 0.01% 500
2018
Q1 		– Sell
-23,887
Closed -$952K – 1087
2017
Q4 		$952K Buy
23,887
+1,007
+4% +$39.8K 0.01% 565
2017
Q3 		$915K Buy
+22,880
New +$990K 0.01% 593

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KeyBank National Association's SUPN Position: Q4 2019 in Review

KeyBank National Association sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 7,751 shares — an estimated $213K sold.

KeyBank National Association first reported a position in SUPN in Q3 2017 and held it in 8 quarters. The position peaked at $1.14M in Q2 2018. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

  • KeyBank National Association reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • KeyBank National Association sold 7,751 Supernus Pharmaceuticals shares in Q4 2019, an estimated $213K.
  • KeyBank National Association first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 8 quarters.
  • KeyBank National Association's Supernus Pharmaceuticals position peaked at $1.14M in Q2 2018.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on KeyBank National Association's 13F filing for Q4 2019, filed 5 Feb 2020.